Core Viewpoint - Novavax Inc. reported a significant improvement in its financial performance for the fourth quarter and full year of 2025, with shares rising following the announcement [1]. Financial Performance - The company reported fourth-quarter earnings of 11 cents, a notable recovery from a loss of 51 cents in the same quarter last year [2]. - Revenue for the fourth quarter reached $147 million, reflecting a 67% year-over-year increase [2]. Cost Management - Novavax exceeded its 2025 cost-cutting targets for both GAAP and Non-GAAP R&D and SG&A spending, and is tightening future expense goals [2]. - The company now anticipates Non-GAAP R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 [3]. Management Commentary - The President and CEO of Novavax highlighted significant progress in corporate strategy, including achievements under the Sanofi agreement and advancements in R&D efforts [4]. Revenue Guidance - Novavax provided a revenue forecast for 2026, projecting adjusted total revenue between $230 million and $270 million, which is below the consensus estimate of $381.22 million [5]. - The company expects Nuvaxovid product sales to be between $35 million and $45 million, along with adjusted supply sales of $40 million to $50 million [5]. Technical Analysis - The stock is currently trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength [6]. - Over the past 12 months, shares have shown significant growth and are closer to their 52-week highs, reflecting a strong upward trend [6]. Momentum Indicators - The RSI is at 44.45, indicating neutral territory, suggesting the stock is neither overbought nor oversold [7]. - The absence of significant MACD crossovers indicates a stable trend without immediate bullish or bearish pressure [7]. Analyst Consensus - The stock carries a Hold Rating with an average price target of $32.23 [8]. - Recent analyst actions include a Buy rating from BTIG with a target of $19.00, while JP Morgan has an Underweight rating with a lowered target of $6.00 [8].

Financial Data and Key Metrics Changes - The company reported total revenue of $1.1 billion for the full year 2025, a 65% increase year-over-year, including $625 million from non-cash revenue recognition related to Nuvaxovid agreements [30][31] - For Q4 2025, total revenue was $147 million, reflecting a 67% increase compared to Q4 2024 [31][36] - Positive income was reported for both the full year and Q4 2025, indicating improved financial performance [31][38] - Combined R&D and SG&A expenses were reduced by 42% and 53% for Q4 and full year 2025, respectively, while maintaining partnership commitments [32][38] Business Line Data and Key Metrics Changes - Nuvaxovid product sales for Q4 2025 were $20 million, with additional supply sales of $19 million from Matrix-M adjuvant sales [36] - Sanofi's licensing, royalty, and other revenue for Q4 2025 was $98 million, driven by milestone achievements and R&D reimbursements [36] Market Data and Key Metrics Changes - The company noted significant market share gains for Nuvaxovid in Japan, with Takeda achieving over 12% market share [9] - Over 30 million doses of the R21 Matrix-M malaria vaccine have been distributed by Serum Institute [9] Company Strategy and Development Direction - The company has shifted from a singular focus on COVID to a broader strategy that includes partnerships and R&D, aiming for long-term value creation [7][8] - A new partnership with Pfizer for Matrix-M was announced, which could generate billions in revenue through milestones and royalties [8][9] - The company is exploring new formulations and applications for Matrix-M, including potential uses in oncology and hard-to-treat infectious diseases [11][19] Management's Comments on Operating Environment and Future Outlook - The management acknowledged uncertainties in the current macro and regulatory environment for vaccine companies but remains optimistic about the long-term need for vaccines [13] - The company anticipates significant growth opportunities in the vaccine and immunotherapeutic markets, projecting a potential market size exceeding $100 billion by the early 2030s [20][21] Other Important Information - The company ended 2025 with $857 million in cash and accounts receivable, with an additional $80 million in non-dilutive cash expected in Q1 2026 [32][33] - A new credit facility of $330 million was established to support ongoing operations and growth strategy [33] Q&A Session Summary Question: Update on Sanofi's vaccine business with new CEO - Management expressed confidence in the ongoing partnership with Sanofi, noting that interactions remain positive despite leadership changes [51] Question: Prioritization of early pipeline programs - The company is advancing multiple early-stage programs, including C. diff, VZV, and RSV, each at their own pace [54][55] Question: Potential for co-promotions in partnerships - The company is currently focused on partnerships rather than building a commercial framework but remains open to co-promotions if a significant product emerges [60] Question: Timeline for MTAs to become formal partnerships - The timeline for MTAs to evolve into formal partnerships depends on the partners' development progress, with ongoing discussions and data generation [70][72]

Financial Data and Key Metrics Changes - The company reported total revenue of $1.1 billion for the full year 2025, a 65% increase year-over-year, including $625 million from non-cash revenue recognition related to Nuvaxovid agreements [33][34] - For Q4 2025, total revenue was $147 million, reflecting a 67% increase compared to Q4 2024 [34][38] - The company achieved positive income for both the full year and Q4 of 2025, indicating improved financial performance [34][40] - Cash and accounts receivables at year-end 2025 totaled $857 million, with an additional $80 million in non-dilutive cash expected in Q1 2026 [35][36] Business Line Data and Key Metrics Changes - Nuvaxovid product sales for Q4 2025 were $20 million, with additional supply sales of $19 million from Matrix-M adjuvant sales [38] - Sanofi licensing, royalty, and other revenue for Q4 2025 was $98 million, primarily driven by milestone achievements [38] Market Data and Key Metrics Changes - The company noted a 12% market share for Nuvaxovid in Japan, with over 30 million doses of the R21/Matrix-M malaria vaccine distributed [10] - The global vaccine market is projected to exceed $60 billion in the next four to five years, with the immunotherapeutic vaccines subset in oncology expected to reach over $42 billion by 2032 [23] Company Strategy and Development Direction - The company has shifted from a COVID-focused organization to one that emphasizes long-term value through partnerships and R&D, supported by a lean operating model [8][9] - The partnership with Pfizer for Matrix-M is expected to generate significant revenue through milestones and royalties [9][10] - The company aims to leverage its Matrix technology to create a portfolio of adjuvants, expanding its utility beyond infectious diseases [12][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainties in the current macro and regulatory environment for vaccine companies but remains optimistic about the long-term need for vaccines [15] - The company anticipates continued progress in 2026, including potential new partnership announcements and advancements in R&D efforts [14][41] Other Important Information - The company has significantly reduced R&D and SG&A expenses, achieving a 42% reduction for Q4 2025 and a 53% reduction for the full year [34][39] - The 2028 guidance for combined R&D and SG&A expenses is set at $200 million or below, representing a 50% decrease compared to 2025 [42][44] Q&A Session Summary Question: Update on Sanofi's vaccine business strategy with new CEO - Management expressed confidence in the ongoing partnership with Sanofi, noting that interactions remain positive despite leadership changes [54] Question: Prioritization of early pipeline programs - The company is advancing multiple early-stage programs, including C. diff, VZV, and RSV, with promising preclinical results [57] Question: Potential for co-promotions in partnerships - The company is currently focused on partnerships rather than building a commercial framework but remains open to co-promotions for significant products in the future [63] Question: Timeline for MTAs to evolve into formal partnerships - The timeline for MTAs to become formal partnerships depends on the partners' development progress, with ongoing discussions and data generation to facilitate these transitions [71][75]

Financial Data and Key Metrics Changes - Total revenue for 2025 reached $1.1 billion, a 65% increase year-over-year, including $625 million from non-cash revenue recognition related to Nuvaxovid agreements [32][33] - Fourth quarter revenue was $147 million, a 67% increase compared to the same period in 2024, with positive income reported for both the full year and fourth quarter [33][35] - Combined R&D and SG&A expenses were reduced by 42% and 53% for the fourth quarter and full year 2025, respectively, while maintaining partnership commitments [33][38] Business Line Data and Key Metrics Changes - Nuvaxovid product sales for the fourth quarter were $20 million, with additional supply sales of $19 million from Matrix-M adjuvant sales [37] - Sanofi's licensing, royalty, and other revenue amounted to $98 million, driven by milestone achievements and R&D reimbursements [37] Market Data and Key Metrics Changes - Takeda achieved over 12% market share for Nuvaxovid in Japan, and more than 30 million doses of the R21 Matrix-M malaria vaccine were distributed [9] - The global vaccine market is projected to exceed $60 billion in the next four to five years, with the immunotherapeutic vaccines subset in oncology expected to reach over $42 billion by 2032 [21][22] Company Strategy and Development Direction - The company has transitioned from a COVID-focused organization to one that emphasizes partnerships and R&D, aiming for long-term value creation through its Matrix technology [6][8] - The growth strategy includes leveraging R&D to expand the utility of Matrix technology beyond infectious diseases and developing new assets for partnerships [10][11] Management's Comments on Operating Environment and Future Outlook - The management acknowledges significant uncertainties in the current macro and regulatory environment for vaccine companies but remains optimistic about the long-term need for vaccines [13] - The company anticipates continued progress in 2026, including potential new partnership announcements and advancements in its R&D pipeline [12][13] Other Important Information - The company ended 2025 with $857 million in cash and accounts receivables, with an additional $80 million in non-dilutive cash expected in early 2026 [34] - A new credit facility of $330 million was established to provide flexibility and access to non-dilutive capital [34] Q&A Session Summary Question: Update on Sanofi's vaccine business with new CEO - Management expressed confidence in the ongoing partnership with Sanofi, noting that interactions remain positive despite the leadership change [51][52] Question: Prioritization of early pipeline programs - The company is advancing multiple early-stage programs, including C. diff, shingles, and RSV, with no specific prioritization disclosed [54] Question: Interest in co-promotions for Matrix-M - The company is currently focused on partnerships rather than building a commercial framework but remains open to co-promotions if a significant opportunity arises [60] Question: Timeline for MTAs to become formal partnerships - The timeline for MTAs to evolve into formal partnerships depends on the partners' development progress, with ongoing discussions and data generation to facilitate these transitions [72][73]

Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights February 26, 2026 © 2026 NOVAVAX. All rights reserved This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate st ...

Core Insights - Novavax has raised its adjusted revenue forecast for 2026 to between $230 million and $270 million, up from a previous estimate of $185 million to $205 million, driven by expected milestone payments from vaccine supply and licensing deals [2][5] - The company reported a fourth-quarter profit of $18 million, a significant turnaround from a net loss of $81 million in the same quarter the previous year, aided by cost cuts and licensing agreements [2][6] - Novavax anticipates reaching profitability by 2028, supported by key product launches, including a COVID-flu combination vaccine developed in partnership with Sanofi [4][5] Revenue and Financial Performance - Fourth-quarter revenue increased by 67% to $147 million, surpassing analysts' expectations of $78.84 million [5] - The adjusted revenue forecast for 2026 reflects a positive outlook despite challenges from declining demand for COVID-19 vaccines [2][3] Strategic Partnerships and Developments - Novavax has licensed its Matrix-M adjuvant technology to Pfizer for up to $530 million, indicating strong interest in its technology [5] - The company is navigating a changing regulatory landscape and has expressed optimism about future vaccine approvals, as seen with the recent developments regarding Moderna's flu vaccine [3][4]

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025 Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for th ...

Vaccine Development and Authorizations - Novavax's COVID-19 Vaccine (Nuvaxovid) has received authorizations from the U.S. FDA, the European Commission, and several other countries for both adult and adolescent populations[34]. - The U.S. FDA approved the BLA for Nuvaxovid in May 2025, triggering a $175 million milestone payment under the Sanofi CLA[35]. - The R21/Matrix-M™ adjuvant malaria vaccine has been authorized in several countries and is developed in collaboration with the Jenner Institute, University of Oxford[23]. - The R21/Matrix-M™ malaria vaccine received prequalification by the World Health Organization (WHO) in December 2023[65]. - The company is developing the R21/Matrix-M™ malaria vaccine and Nuvaxovid® COVID-19 Vaccine in collaboration with partners[97]. Financial Performance and Obligations - The company recognized $575.7 million in product sales during the year ended December 31, 2025, due to the termination of the Canada APA[30]. - Novavax is eligible to receive milestone payments totaling up to $350 million related to COVID-19 Vaccine products, with $75 million remaining outstanding as of December 31, 2025[55]. - The company reported a net income of $440.3 million in 2025, following losses of $187.5 million in 2024 and $545.1 million in 2023, indicating significant fluctuations in financial performance[153]. - The accumulated deficit reached $4.6 billion as of December 31, 2025, reflecting a history of losses since its formation in 1987[153]. - As of December 31, 2025, the company classified $48.4 million as current deferred revenue and $85.4 million as non-current deferred revenue related to the Australia APA[164]. Research and Development Focus - Novavax's pipeline includes a combination vaccine for COVID-19 and seasonal influenza, currently in Phase 3[33]. - The company is advancing its pipeline programs with a focus on high-value assets in areas with unmet medical needs[20]. - Novavax is advancing its pipeline with a focus on high-value assets in unmet medical needs, including early-stage research in diseases such as C. Diff, shingles, and RSV combinations[39]. - The company aims to partner its early-stage pipeline programs at proof of concept, focusing on capital-efficient R&D investments[39]. - The company initiated a Phase 3 immunogenicity and safety trial for its CIC and stand-alone influenza vaccine candidates in December 2024, with approximately 2,000 participants enrolled[72]. Regulatory and Compliance Challenges - The company must navigate extensive regulatory requirements for vaccine development, which require substantial time and financial resources[96]. - The FDA's review process for a Biologics License Application (BLA) typically aims for completion within ten months for standard applications and six months for priority reviews[109]. - The company is subject to various risks related to compliance with healthcare regulations, which could result in significant penalties and operational restrictions[143]. - Regulatory scrutiny and legislative efforts to control drug pricing may affect demand and pricing strategies for the company's product candidates[134][135]. - The company faces significant risks in developing and commercializing its vaccine candidates, with a high uncertainty regarding the success of research and development programs[200]. Market and Competitive Landscape - The company faces competition from larger firms with greater resources, which may impact its commercial opportunities[155]. - Third-party payers increasingly challenge pricing and cost-effectiveness of medical products, impacting sales and financial results[126][128]. - Changes in government policies and healthcare reform initiatives may impact drug pricing and reimbursement, potentially affecting profitability[131][134]. - The emergence of new variants of the SARS-CoV-2 virus may negatively impact market acceptance and sales of the COVID-19 Vaccine[197]. - Market acceptance of the vaccine candidates is crucial for revenue generation, and failure to gain acceptance could materially affect the company's financial condition[214]. Operational and Supply Chain Considerations - The company relies on third parties for conducting preclinical studies and clinical trials, which poses risks to the timely completion of development programs[155]. - The company relies on a single source supplier for quillaja extract, which is critical for the development and manufacture of its adjuvant products[216]. - Long-term access to quillaja extract with consistent and high quality is essential for maintaining a secure supply of raw material[216]. - The key component of the adjuvant technology is extracted from the Quillaja saponaria species, which is grown in Chile[216]. - The company has a supply agreement with SLS for the manufacture of the antigen component of the COVID-19 Vaccine, which includes specific quantities to be delivered under the SLS Supply Agreement[68]. Employee and Organizational Development - The company has a team of approximately 749 employees as of December 31, 2025, critical to its success in research and development[81]. - The company provides an Executive Development Program for 20 high-potential employees annually to prepare them for future leadership roles[88]. - The company offers various employee training opportunities, including health and safety measures and well-being programs[97]. Sustainability and Ethical Practices - The company focuses on sustainability through four strategic pillars aimed at positively impacting global health and operating sustainably[89]. - The company is committed to responsible animal welfare practices, adhering to the 3R principle (Reduce, Refine, Replace)[91]. - The company aligns its sustainability reporting with frameworks such as SASB and GRI to accurately reflect pertinent topics in the biotechnology industry[97].

Group 1 - Novavax, Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, at 8:30 a.m. ET [1] - The conference call will include details on how to join and will be available for replay from February 26, 2026, until March 5, 2026 [1] - Novavax focuses on addressing global health challenges through its vaccine technology, including the Matrix-M® adjuvant and protein-based nanoparticles [1] Group 2 - The company aims to maximize the impact of its technology by forming strategic partnerships for its Matrix-M adjuvant and R&D assets [1] - Contact information for investor relations and media inquiries is provided, indicating the company's commitment to communication with stakeholders [1]

Company Performance - Novavax (NVAX) closed at $8.97, reflecting a +2.51% increase from the previous day, outperforming the S&P 500 which had a daily loss of 0.01% [1] - Over the past month, Novavax shares gained 0.92%, while the Medical sector and S&P 500 experienced losses of 1.31% and 0.28% respectively [1] Earnings Expectations - The upcoming earnings report for Novavax is expected to show an EPS of -$0.66, a decline of 29.41% compared to the same quarter last year [2] - Revenue is anticipated to be $78.41 million, indicating an 11.21% decrease from the same quarter of the previous year [2] Full-Year Estimates - Zacks Consensus Estimates project full-year earnings of $1.94 per share and revenue of $1.05 billion, representing year-over-year increases of +257.72% and +54.62% respectively [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Novavax are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 ranked stocks have yielded an average annual return of +25% since 1988 [6] - Novavax currently holds a Zacks Rank of 3 (Hold), with a 9.04% increase in the Zacks Consensus EPS estimate over the last 30 days [6] Industry Context - Novavax operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [7]